WooGene B&G Co., Ltd (KOSDAQ:018620)

South Korea flag South Korea · Delayed Price · Currency is KRW
885.00
+2.00 (0.23%)
Last updated: Nov 19, 2025, 9:00 AM KST
0.23%
Market Cap25.57B
Revenue (ttm)53.25B
Net Income (ttm)-5.03B
Shares Out28.89M
EPS (ttm)-174.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume14,050
Average Volume55,547
Open884.00
Previous Close883.00
Day's Range862.00 - 889.00
52-Week Range815.00 - 1,027.00
Beta0.37
RSI52.64
Earnings DateNov 13, 2025

About WooGene B&G

WooGene B&G Co., Ltd. engages veterinary medicines, microbial technology, and vaccines business in South Korea and internationally. It offers antibiotic, vaccine, nutrient, anti-inflammation, metabolic stimulant, and iron supplement products for swine, poultry, cattle, aquatic animals, companion animals, and raw materials, as well as operates vaccine research center. The company was formerly known as WooJin Co., Ltd. and changed its name to WooGene B&G Co., Ltd. in March 2001. WooGene B&G Co., Ltd. was founded in 1977 and is headquartered in Hw... [Read more]

Industry Pharmaceutical Preparations
Founded 1977
Employees 99
Stock Exchange KOSDAQ
Ticker Symbol 018620
Full Company Profile

Financial Performance

In 2024, WooGene B&G's revenue was 55.68 billion, a decrease of -3.87% compared to the previous year's 57.92 billion. Losses were -5.22 billion, 341.0% more than in 2023.

Financial Statements

News

There is no news available yet.